Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New...( SAN CARLOS Calif. Oct. 7 /- Nekta...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
Date:10/7/2008
SAN CARLOS, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) President and CEO Howard W. Robin is scheduled to present at the upcoming Natixis Bleichroeder Second Annual Hidden Gems Conference in New York at the Waldorf-Astoria Hotel on Monday, October 13, 2008 at 2:30 p.m. ET.
The presentation will be accessible via Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 27, 2008.
About Nektar
Nektar Therapeutics is a biopharmaceutical company that develops and
enables differentiated therapeutics with its industry-leading PEGylation
and pulmonary drug development technology platforms. Nektar PEGylation and
pulmonary technology, expertise, manufacturing capabilities have enabled
eight approved products for partners, which include the world's leading
pharmaceutical and biotechnology companies. Nektar also develops its own
products by applying its PEGylation and pulmonary technology platforms to
existing medicines with the objective to enhance performance, such as
improving efficacy, safety and compliance.
CONTACT:
Stephan Herrera
Nektar Therapeutics
1-415-488-7699
'/>"/>
| SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
Breaking Biology Technology:Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Dendreon Appoints Hans Bishop as Chief Operating Officer 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3
[0] Brooks Instrument Appoints Mike Bayda as Global Level Product Manager [0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head[0] Dendreon Appoints Hans Bishop as Chief Operating Officer[0] Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
Other Biology Technology:Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 10Oncothyreon reports third quarter 2008 financial results 2Oncothyreon reports third quarter 2008 financial results 3Oncothyreon reports third quarter 2008 financial results 4Oncothyreon reports third quarter 2008 financial results 5Accuray Postpones Release of First Quarter Fiscal 2009 Results 2
Breaking Biology News(10 mins):Experts: Disease-resistant plants enhance profits, client satisfaction 2Climate projections underestimate CO2 impact 2A Swiss Team Uses Transcranial MR Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders 13006 1A Swiss Team Uses Transcranial MR Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders 13006 2A Swiss Team Uses Transcranial MR Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders 13006 3Obesity Contributes to Rapid Cartilage Loss 51575 1Obesity Contributes to Rapid Cartilage Loss 51575 2Obesity Contributes to Rapid Cartilage Loss 51575 3Obesity Contributes to Rapid Cartilage Loss 51575 4Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 1Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 2Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 3Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 4
Other Biology News:Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska 2Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska 3Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska 4Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska 5Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska 6Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska 7Masks, hand washing, prevent spread of flu-like symptoms by up to 50 percent 2Masks, hand washing, prevent spread of flu-like symptoms by up to 50 percent 3Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 2Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 3Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 4Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 5Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics 6
Biology Products:
Chicken Anti-Rab GDP dissociation inhibitor beta Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.Nanoject II, 220 VOLT from Drummond Scientific CompanyBD BioCoat Poly-D-Lysine 35 mm Culture Dishes from BD Biosciences - Discovery LabwareRabbit Anti-Synapsin II Polyclonal Antibody, Unconjugated from Abcam
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |